# Cohance Lifesciences share price today (Cohance Lifesciences Ltd, NSE: COHANCE)

> Cohance Lifesciences share price today: ₹450.45 at the NSE close on 4 November 2026, down 36.3% in a year. Cohance Lifesciences (NSE: COHANCE) is worth ₹17,246 crore, trades at a P/E of 160.3 and has closed between ₹279.90 and ₹707.60 over the past 52 weeks. > Cohance Lifesciences Ltd's share price has risen faster than its earnings: −36.3% in a year, against −75.5% for earnings per share. COHANCE · Pharma - API & CRAMS · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from fewer quarters than usual
- Price: ₹450.45 (−36.3% in a year)
- P/E: 160.3× (higher than 99% of the last 6.6 years)
- Revenue (Jun 2026): ₹422 Cr (−23.1% on a year ago)
- Profit (Jun 2026): −₹45.0 Cr (−197.8% on a year ago)
- Operating margin: 0.3% (−19.7 points on a year ago)
- ROCE: 6%, FY26
- Profit that came in as cash: 150%, last 3 years

The main question: the share price moved −36.3% in a year while yearly earnings per share moved −75.5%. The difference came from the market paying a higher multiple. ## What is the Cohance Lifesciences share price today? Cohance Lifesciences Ltd's share price was ₹450.45 at the close on 4 November 2026. It has been falling for 71 weeks. That is 7.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹280 and ₹708, and at that close it sat 40% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 7 weeks in a row. Over the last 6.6 years the share price moved +209% while the NIFTY 500 moved +212%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Cohance Lifesciences this quarter? Three changes stood out: lowest operating margin in 15 quarters, profit down on a year earlier for 5 quarters in a row and revenue down on a year earlier for 4 quarters in a row. 1. Lowest operating margin in 15 quarters Operating margin was 0.3% in the June 2026 quarter, against 20% a year earlier. Why: Margins fell because the higher-margin pharma CDMO business brought in less and product mix got worse. Next results: check whether commercial deliveries, payload execution, customer approvals and factory use lift margins, since management said margin recovery is weighted to the second half. From the earnings call on 5 Aug 2026. 2. Profit down on a year earlier for 5 quarters in a row In the June 2026 quarter profit was ₹-45 crore, -197.8% on a year earlier. Why: Profit fell because revenue dropped, margins shrank, and NJ Bio ran a large loss while its costs stayed high. From the earnings call on 5 Aug 2026. 3. Revenue down on a year earlier for 4 quarters in a row In the June 2026 quarter revenue was ₹422 crore, -23.1% on a year earlier. Why: Revenue fell because customers moved pharma CDMO shipments out of the quarter. Next results: check whether scheduled commercial deliveries and restocking orders bring revenue back, since management called Q1 the trough. From the earnings call on 5 Aug 2026. ## What are Cohance Lifesciences' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Cohance Lifesciences reported revenue of ₹422 crore, down 23.1% from ₹549 crore a year earlier, and a loss of ₹45.0 crore, down 197.8% from ₹46.0 crore. ### Cohance Lifesciences results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹422 crore | ₹549 crore | −23.1% |
| Profit | loss of ₹45.0 crore | ₹46.0 crore | −197.8% |
| Earnings per share | ₹−0.63 | ₹1.28 | −149.2% |
| Operating margin | 0.3% | 20.0% | −19.7 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Cohance Lifesciences' management discussed these results on a call held on 5 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Cohance Lifesciences share price history? Cohance Lifesciences closed at ₹450.45 on 4 November 2026, down 36.3% from ₹707.60 a year earlier (7 November 2025) and down 11.3% over five years. Its highest weekly close since March 2020 was ₹1,327.15 on 1 November 2024. ### Cohance Lifesciences share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹444.30 | +1.4% |
| 1 month ago · 1 Oct 2026 | ₹451.30 | −0.2% |
| 6 months ago · 8 May 2026 | ₹488.20 | −7.7% |
| 1 year ago · 7 Nov 2025 | ₹707.60 | −36.3% |
| 3 years ago · 3 Nov 2023 | ₹557.00 | −19.1% |
| 5 years ago · 4 Nov 2021 | ₹507.75 | −11.3% |
| Earliest weekly close in our records · 13 Mar 2020 | ₹145.65 | +209.3% |
| Highest weekly close since March 2020 · 1 Nov 2024 | ₹1,327.15 | −66.1% |
| Lowest weekly close since March 2020 · 27 Mar 2020 | ₹103.60 | +334.8% |
| 52-week high (weekly close) · 7 Nov 2025 | ₹707.60 | −36.3% |
| 52-week low (weekly close) · 6 Mar 2026 | ₹279.90 | +60.9% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (353 weekly closes from 13 March 2020 to 4 November 2026.)

## What is the latest news on Cohance Lifesciences? 4 Nov 2026: Cohance Lifesciences closed at ₹450.45, up 1.4% on the week and down 0.2% on the month. 5 Aug 2026: Cohance Lifesciences held its results call for April to June 2026. Management guided: Q2 sequential improvement, year-on-year comparability by end-H1 and year-on-year growth from H2 FY27; margin recovery weighted to H2. ### Earlier

- Results for April to June 2026: Revenue down 23.1% and profit down 197.8% on a year earlier. ## What dividend does Cohance Lifesciences pay? Cohance Lifesciences paid no dividend in the 12 months to 5 November 2026. The last was an interim + special dividend of ₹6 a share, ex-date 9 September 2022. ### Cohance Lifesciences dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 9 Sep 2022 | ₹6 | Interim + Special | 12 Sep 2022 |
| 13 May 2022 | ₹2 | Interim + Special | 17 May 2022 |
| 15 Feb 2022 | ₹3 | Interim + Special | 16 Feb 2022 |
| 13 Aug 2021 | ₹1 | Dividend | 17 Aug 2021 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 2 of 5 Of the last 5 financial years, years with an NSE dividend record

Not in its latest year. Cohance Lifesciences Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 4 of its last 8 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Cohance Lifesciences management say on the latest results call? On the call for April to June 2026, held on 5 August 2026, Cohance Lifesciences' management guided: Q2 sequential improvement, year-on-year comparability by end-H1 and year-on-year growth from H2 FY27; margin recovery weighted to H2. > “At this point, I am almost feeling that the target is an aspiration. I am not sure that we are at a point where we can say how close we will be to it, whether we will fall short of it or whether we will exceed it.”
> Umang Vohra, on the call for April to June 2026

### What management guided

- Operating margin expected nearer the previous year's percentage in FY27, then accelerate from FY28. - Two recently commercialized molecules are scheduled to deliver six intermediates across Q2-Q3; customized ADC payload due Q2. - Restocking order for one commercial molecule to provide delivery visibility across January to March 2027 and FY28. - API Plus: 7 new API filings in FY27, 2 formulation launches in Q2 and around 10 launches across the fiscal year. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/39029/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 5 August 2026.)

## What to watch in Cohance Lifesciences' next results? When Cohance Lifesciences reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Q2 sequential improvement - check commercial deliveries, payload execution, customer approvals and utilization. - What to check (from the call)
- Q2 sequential improvement - check commercial deliveries, payload execution, customer approvals and utilization. - API Plus filings and formulation launches - check conversion into revenue and whether segment resilience persists. - NJ Bio FTE renewal and revenue conversion - check whether biotech funding pressure eases and consolidated drag narrows. - Pashamylaram CAPA response and agency outcome - check for escalation beyond the stated observations. ## Which stock lists is Cohance Lifesciences on? Cohance Lifesciences is on 2 of our India lists: Small & mid cap stocks and Pharma stocks. - [Small & mid cap stocks Size rank in India: 388](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 17234.30013504389](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Cohance Lifesciences profitable? Cohance Lifesciences Ltd posted a net loss of ₹45.0 Cr in the Jun 2026 quarter. Full-year FY26 profit was ₹150 Cr. Over 7 years profit has grown 4.7% a year on average. That loss is 10.7% of the quarter's revenue. The same quarter a year earlier earned ₹46.0 Cr. 1 of the last 12 reported quarters were loss-making. Jun 2026 profit was −₹45.0 Cr, −197.8% on a year earlier. For the full year, FY26 profit was ₹150 Cr (−69.0% on the year before). Why profit moved: revenue changed −23.1% on a year earlier and the margin moved −19.7 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −106.0% and revenue −19.2%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Cohance Lifesciences make, and is it growing? Cohance Lifesciences Ltd reported ₹422 Cr of revenue in the Jun 2026 quarter, −23.1% on the same quarter a year earlier. Over 7 years it has grown 29.2% a year on average. The last full year, FY26, came in at ₹2,269 Cr. The last four reported quarters add to ₹2,142 Cr. FY26 revenue was ₹2,269 Cr, −13.0% on the year before. Recent pace: the last four quarters grew −19.2% on average, against 29.2% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −19.7%, against +34.1% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −87.2%, against −52.3% a year (rolling over). ## How much of every ₹100 of sales does Cohance Lifesciences keep? Cohance Lifesciences Ltd's operating margin was 0.3% in the Jun 2026 quarter, 19.7 percentage points lower than the same quarter a year ago. Across 8 years it has been between 19.0% and 46.0%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −20.1 percentage points on the year while gross margin changed −1.5 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Cohance Lifesciences' profit turning into cash? Over the last 3 years, 150% of Cohance Lifesciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹368 Cr of operating cash against ₹150 Cr of profit. After ₹293 Cr of spending on assets, ₹75.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 150% of profit came in as cash: the cash cycle got 83 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 7.6× depreciation over three years. The next section checks what that spending is building. ## Where does Cohance Lifesciences' cash go? Cohance Lifesciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 263 days in FY26, up from 180 days in FY21. It spent ₹3,128 Cr on assets over the last 3 years. Customers take 110 days to pay, and stock sits for 310 days on average. At FY26 sales of ₹2,269 Cr, each day of that cycle ties up about ₹6.2 Cr, so roughly ₹1,635 Cr is tied up in the business at any time. FY26: customers took 110 days to pay and stock sat for 310 days, about 10.2 months of sales sitting as stock, for a full cycle of 263 days, longer than FY21's 180. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 310 days. Customers pay about 110 days after that. Suppliers are paid at 157 days. Together that makes the 263-day cycle. Spending on assets: ₹3,128 Cr over the last 3 years, against ₹409 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹178 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Cohance Lifesciences' P/E ratio, and how does it compare with its own history? Cohance Lifesciences Ltd's P/E is 160.3×, about the highest it has ever been. Its usual P/E (the middle reading) is 38.5×, over 6.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹2.78. Why the multiple is where it is: over the past year earnings per share moved −75.5% while the price moved −36.3%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved −2.4% a year; about −28.3% a year came from earnings growth and about +25.9 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 138% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Cohance Lifesciences business getting better or worse? Cohance Lifesciences Ltd's business is getting worse. Revenue, profit and EPS growth are shrinking: revenue growth is −19.7% in the latest quarter, against +147.9% at its best in 12 quarters, with ROCE falling at 6.0%. This is based on 8 quarters of 4 measures, with some gaps. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Cohance Lifesciences earn on its capital? Cohance Lifesciences Ltd earned a ROCE of 6% in FY26. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 6.6% net margin and 0.40× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 6.6% net margin × 0.40× asset turnover × 1.46× leverage (assets divided by equity) ≈ 3.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 138% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Cohance Lifesciences have too much debt? Cohance Lifesciences Ltd had ₹400 Cr of borrowings against ₹3,911 Cr of equity in FY26, so its debt is 0.10× its equity. Its operating profit is 12 times its interest bill. Over 5 years borrowings went from ₹143 Cr to ₹400 Cr. Over the last 3 of those years it spent ₹3,128 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 138% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Cohance Lifesciences shareholding pattern? Promoters raised their stake in Cohance Lifesciences Ltd by 7.4 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 57.5% of the company. Foreign institutions moved −3.0 points over the same period, to 7.7%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: +7.4 points over 8 quarters, to 57.5%; Foreign institutions: −3.0 points over 8 quarters, to 7.7%; Domestic institutions: +1.9 points over 8 quarters, to 18.9%. Why the owners changed: foreign institutions moved −3.0 points and domestic institutions +1.9 points over 8 quarters, while promoters moved +7.4 points. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Cohance Lifesciences from balance-sheet trouble? For Cohance Lifesciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Cohance Lifesciences rank in its industry? 27.1 out of 100, rank 23 of 24 in Pharma - API & CRAMS, with 78% of the evidence available. Cohance Lifesciences Ltd scores 27.1 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 23. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 5 + 6.7 + 5.5 + 9.9 = 27.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Cohance Lifesciences compared with? Cohance Lifesciences ranks 23 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 27.1 out of 100. 1. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) NEULANDLAB · leader · Most evidence points up · 96% evidence 76.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.3/35 · Revenue 78.3% · Profit 100% · Operating margin change 23 points · 88% evidence Capital efficiency 22.9/25 · ROCE 26.5% · Operating margin 35% · 100% evidence Valuation 14.1/20 · P/E 50.8× · PEG 1.04 · 100% evidence Relative strength 6.7/20 · Lead over its industry -7.8% · Lead over NIFTY 500 20.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.3 + 22.9 + 14.1 + 6.7 = 76 · What this means: Earnings are strong; relative strength in its sector is -7.8% and the one-year return is 19.6%. 2. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ACUTAAS · turning · Most evidence points up · 67% evidence 73.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 45.4% · Profit 95.5% · Operating margin change 9 points · 95% evidence Capital efficiency 20.3/25 · ROCE 31.6% · Operating margin 40% · 76% evidence Valuation 10.2/20 · P/E 74.6× · PEG n/a · 50% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 59.6% · 1 year 131.7% · 25% evidence · 2 of 9 weeks ahead Exact sum: 31.3 + 20.3 + 10.2 + 12.1 = 73.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Laurus Labs Ltd](https://www.sectoralpha.in/stocks/laurus-labs-ltd) LAURUSLABS · leader · Most evidence points up · 93% evidence 71.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.9/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidence Capital efficiency 17.3/25 · ROCE 17.8% · Operating margin 34% · 100% evidence Valuation 5.8/20 · P/E 97× · PEG 2.98 · 65% evidence Relative strength 17.0/20 · Lead over its industry 42.3% · Lead over NIFTY 500 82.8% · 1 year 152.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.9 + 17.3 + 5.8 + 17 = 71 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) GLAND · leader · Most evidence points up · 96% evidence 69.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 17.6% · Profit 46.4% · Operating margin change 3 points · 88% evidence Capital efficiency 16.0/25 · ROCE 15.1% · Operating margin 27% · 100% evidence Valuation 12.1/20 · P/E 44.6× · PEG 1.45 · 100% evidence Relative strength 16.8/20 · Lead over its industry 15.1% · Lead over NIFTY 500 49.3% · 1 year 60.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25 + 16 + 12.1 + 16.8 = 69.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) IOLCP · leader · Most evidence points up · 100% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.3% · Operating margin 14% · 100% evidence Valuation 13.9/20 · P/E 24.6× · PEG 0.66 · 100% evidence Relative strength 13.9/20 · Lead over its industry 21.6% · Lead over NIFTY 500 53.8% · 1 year 92.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.1 + 12.8 + 13.9 + 13.9 = 69.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) SHILPAMED · leader · Most evidence points up · 89% evidence 67.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 28% · Profit 100% · Operating margin change 1 points · 88% evidence Capital efficiency 10.8/25 · ROCE 10.9% · Operating margin 29% · 100% evidence Valuation 9.9/20 · P/E 65.7× · PEG 1.73 · 65% evidence Relative strength 19.9/20 · Lead over its industry 47.2% · Lead over NIFTY 500 84.2% · 1 year 170.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.4 + 10.8 + 9.9 + 19.9 = 67 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) MOREPENLAB · leader · Evidence leans up · 85% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidence Capital efficiency 9.3/25 · ROCE 8.1% · Operating margin 16% · 100% evidence Valuation 8.5/20 · P/E 32.9× · PEG 2.14 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 94.5% · 1 year 139% · 25% evidence · 12 of 12 weeks ahead Exact sum: 31.8 + 9.3 + 8.5 + 12.5 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) DIVISLAB · leader · Evidence leans up · 96% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue 16.4% · Profit 26.8% · Operating margin change 11 points · 88% evidence Capital efficiency 18.6/25 · ROCE 22% · Operating margin 41% · 100% evidence Valuation 2.6/20 · P/E 87.1× · PEG 3.45 · 100% evidence Relative strength 15.5/20 · Lead over its industry 9.2% · Lead over NIFTY 500 43.1% · 1 year 45.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.7 + 18.6 + 2.6 + 15.5 = 61.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 9. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) GRANULES · turning · Evidence leans up · 96% evidence 57.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 24.8% · Profit 38.1% · Operating margin change 3 points · 88% evidence Capital efficiency 16.2/25 · ROCE 15.5% · Operating margin 23% · 100% evidence Valuation 10.2/20 · P/E 35.2× · PEG 1.29 · 100% evidence Relative strength 6.7/20 · Lead over its industry -5.2% · Lead over NIFTY 500 24.2% · 1 year 48.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.3 + 16.2 + 10.2 + 6.7 = 57.4 · What this means: Earnings are strong; relative strength in its sector is -5.2% and the one-year return is 48.5%. 10. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) SAILIFE · leader · Evidence leans up · 89% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 17.6% · Profit 48% · Operating margin change 3 points · 88% evidence Capital efficiency 17.0/25 · ROCE 19.6% · Operating margin 27% · 100% evidence Valuation 4.8/20 · P/E 90× · PEG 3.63 · 65% evidence Relative strength 13.8/20 · Lead over its industry 9.9% · Lead over NIFTY 500 42.9% · 1 year 69.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.7 + 17 + 4.8 + 13.8 = 57.3 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) SMSPHARMA · breaking out · Evidence leans up · 96% evidence 55.8 out of 100 Growth Capital Valuation Relative
12. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) BLUEJET · quiet · Evidence leans up · 81% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) SOLARA · breaking out · Evidence leans down · 74% evidence 49.5 out of 100 Growth Capital Valuation Relative
14. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) WINDLAS · leader · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
15. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ANTHEM · leader · Evidence leans down · 89% evidence 46.7 out of 100 Growth Capital Valuation Relative
16. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) PPLPHARMA · leader · Evidence leans down · 71% evidence 44.6 out of 100 Growth Capital Valuation Relative
17. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) SUPRIYA · breaking out · Evidence leans down · 96% evidence 43.7 out of 100 Growth Capital Valuation Relative
18. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) CONCORDBIO · quiet · Evidence leans down · 85% evidence 40.8 out of 100 Growth Capital Valuation Relative
19. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) JUBLPHARMA · turning · Most evidence points down · 86% evidence 30.3 out of 100 Growth Capital Valuation Relative
20. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) HIKAL · turning · Most evidence points down · 78% evidence 29.7 out of 100 Growth Capital Valuation Relative
21. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ONESOURCE · turning · Most evidence points down · 83% evidence 29.2 out of 100 Growth Capital Valuation Relative
22. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) SYNGENE · turning · Most evidence points down · 100% evidence 27.8 out of 100 Growth Capital Valuation Relative
23. Cohance Lifesciences Ltd this page COHANCE · breaking out · Most evidence points down · 78% evidence 27.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 5.0/35 · Revenue -19.8% · Profit -80% · Operating margin change -19.7 points · 83% evidence Capital efficiency 6.7/25 · ROCE 5.8% · Operating margin 0.3% · 76% evidence Valuation 5.5/20 · P/E 158× · PEG n/a · 50% evidence Relative strength 9.9/20 · Lead over its industry -19.7% · Lead over NIFTY 500 7.1% · 1 year -41% · 100% evidence · 7 of 12 weeks ahead Exact sum: 5 + 6.7 + 5.5 + 9.9 = 27.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 24. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) DCAL · basing · Most evidence points down · 64% evidence 27.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API & CRAMS](https://www.sectoralpha.in/sectors/pharma-api-crams), all 24 compared on one page. ## Which companies are close to Cohance Lifesciences in size? Cohance Lifesciences is the 12th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Granules India, Shilpa Medicare and OneSource Specialty Pharma. Just below it: Syngene International, Jubilant Pharmova and Concord Biotech. ### Pharma - API & CRAMS companies close in size

1. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) ₹22,907 crore
2. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) ₹18,690 crore
3. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ₹17,924 crore
4. Cohance Lifesciences Ltd ₹16,999 crore
5. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) ₹16,256 crore
6. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) ₹14,716 crore
7. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) ₹13,031 crore

[All 24 Pharma - API & CRAMS companies, largest first](https://www.sectoralpha.in/sectors/pharma-api-crams#all-companies)

### Companies close in size in other industries

1. [International Gemological Institute Limited](https://www.sectoralpha.in/stocks/international-gemological-institute-limited) ₹17,189 crore · Lab Grown Diamonds
2. [The Ramco Cements Ltd](https://www.sectoralpha.in/stocks/the-ramco-cements-ltd) ₹17,005 crore · Cement
3. Cohance Lifesciences Ltd ₹16,999 crore
4. [LMW Ltd](https://www.sectoralpha.in/stocks/lmw-ltd) ₹16,977 crore · Textile machinery
5. [Sigma Advanced System Ltd](https://www.sectoralpha.in/stocks/sigma-advanced-system-ltd) ₹16,915 crore · Aerospace & Defence - Equipments

## What else do people ask about Cohance Lifesciences? ### What is Cohance Lifesciences's share price today? Cohance Lifesciences Ltd's share price is ₹450.45, −36.3% over the past year. The whole company is worth ₹17,246 Cr on the market. In the last 52 weeks it traded between ₹280 to ₹708; today it is 40% of the way up from the low, 7.0% below its 200-day average (as of 4 November 2026). ### What were Cohance Lifesciences's latest quarterly results? Cohance Lifesciences Ltd reported revenue of ₹422 Cr and a net loss of ₹45.0 Cr for the Jun 2026 quarter. Revenue fell 23.1% and profit fell 197.8% compared with a year earlier. Earnings per share were −₹0.63. The operating margin was 0.3%, 19.7 percentage points lower than a year earlier (as of 4 November 2026). ### What is Cohance Lifesciences's market cap? Cohance Lifesciences Ltd's market capitalisation is ₹17,246 Cr at a share price of ₹450.45. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Cohance Lifesciences performing? Cohance Lifesciences Ltd's share price has been falling for 71 weeks. In its latest quarter, revenue fell 23.1% and profit fell 197.8% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 7 weeks running (as of 4 November 2026). ### Will Cohance Lifesciences's share price go up? This page does not forecast Cohance Lifesciences Ltd's share price. What it shows instead: the share price is ₹450.45, and it has been falling for 71 weeks. Its P/E of 160.3× is higher than 99% of its own last 7 years (as of 4 November 2026). ### Who owns Cohance Lifesciences? Promoters own 57.5% of Cohance Lifesciences Ltd, foreign institutions 7.7%, domestic institutions 18.9% and the public 15.9% (latest quarter). The biggest change over the last two years: Promoters raised their stake by 7.4 percentage points over 8 quarters (as of 4 November 2026). ### Where is Cohance Lifesciences in its business cycle? Cohance Lifesciences Ltd's FY26 operating margin was 19.0%, against a 8-year range of 19.0% to 46.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 0.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Cohance Lifesciences story? The main question: the share price moved −36.3% in a year while yearly earnings per share moved −75.5%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Cohance Lifesciences a stock worth studying right now? What the numbers show: Cohance Lifesciences Ltd's share price has risen faster than its earnings: −36.3% in a year, against −75.5% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Cohance Lifesciences share price forecast for 2026? What management itself guided: Q2 sequential improvement, year-on-year comparability by end-H1 and year-on-year growth from H2 FY27; margin recovery weighted to H2. ## Lists

- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.